Repository logo
 

Coronary Plaque Morphology and the Anti-Inflammatory Impact of Atorvastatin: A Multicenter 18F-Fluorodeoxyglucose Positron Emission Tomographic/Computed Tomographic Study.

Accepted version
Peer-reviewed

Change log

Authors

Singh, Parmanand 
Emami, Hamed 
Subramanian, Sharath 
Maurovich-Horvat, Pal 
Marincheva-Savcheva, Gergana 

Abstract

BACKGROUND: Nonobstructive coronary plaques manifesting high-risk morphology (HRM) associate with an increased risk of adverse clinical cardiovascular events. We sought to test the hypothesis that statins have a greater anti-inflammatory effect within coronary plaques containing HRM. METHODS AND RESULTS: In this prospective multicenter study, 55 subjects with or at high risk for atherosclerosis underwent 18F-fluorodeoxyglucose positron emission tomographic/computed tomographic imaging at baseline and after 12 weeks of treatment with atorvastatin. Coronary arterial inflammation (18F-fluorodeoxyglucose uptake, expressed as target-to-background ratio) was assessed in the left main coronary artery (LMCA). While blinded to the PET findings, contrast-enhanced computed tomographic angiography was performed to characterize the presence of HRM (defined as noncalcified or partially calcified plaques) in the LMCA. Arterial inflammation (target-to-background ratio) was higher in LMCA segments with HRM than those without HRM (mean±SEM: 1.95±0.43 versus 1.67±0.32 for LMCA with versus without HRM, respectively; P=0.04). Moreover, atorvastatin treatment for 12 weeks reduced target-to-background ratio more in LMCA segments with HRM than those without HRM (12 week-baseline Δtarget-to-background ratio [95% confidence interval]: -0.18 [-0.35 to -0.004] versus 0.09 [-0.06 to 0.26]; P=0.02). Furthermore, this relationship between coronary plaque morphology and change in LMCA inflammatory activity remained significant after adjusting for baseline low-density lipoprotein and statin dose (β=-0.27; P=0.038). CONCLUSIONS: In this first study to evaluate the impact of statins on coronary inflammation, we observed that the anti-inflammatory impact of statins is substantially greater within coronary plaques that contain HRM features. These findings suggest an additional mechanism by which statins disproportionately benefit individuals with more advanced atherosclerotic disease. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00703261.

Description

Keywords

atherosclerosis, carotid artery, coronary artery disease, inflammation, positron emission tomography, Adult, Aged, Anti-Inflammatory Agents, Atorvastatin, Biomarkers, Computed Tomography Angiography, Coronary Angiography, Coronary Artery Disease, Coronary Vessels, Double-Blind Method, Female, Fluorodeoxyglucose F18, Humans, Inflammation Mediators, Male, Middle Aged, Plaque, Atherosclerotic, Positron Emission Tomography Computed Tomography, Predictive Value of Tests, Prospective Studies, Radiopharmaceuticals, Risk Factors, Severity of Illness Index, Time Factors, Treatment Outcome, United States, Vascular Calcification

Journal Title

Circ Cardiovasc Imaging

Conference Name

Journal ISSN

1941-9651
1942-0080

Volume Title

9

Publisher

Ovid Technologies (Wolters Kluwer Health)
Sponsorship
British Heart Foundation (None)
British Heart Foundation (None)
National Heart, Lung, and Blood Institute of the National Institutes of Health (5T32 HL076136) and Marfan Foundation, National Institute for Health Research Cambridge Biomedical Research Centre, British Heart Foundation, Wellcome Trust